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Abstract
Objective: Determine the long-term effectiveness of quetiapine in combination with standard
treatments in preventing relapses for patients with bipolar I disorders
Method: Twenty-one outpatients with type I bipolar disorder who had inadequate responses to
ongoing standard therapies were treated with add-on quetiapine in an open-label study. The
quetiapine dose was increased until clinical response occurred. Illness response was assessed using
the Clinical Global Impression (CGI) scale. Relapse rates before and during quetiapine treatment
were compared by calculating incidence risk ratios.
Results: Quetiapine was added to ongoing standard therapy for 26 to 78 weeks. Thirteen patients
received combination therapy for at least 52 weeks. The mean quetiapine dose received was 518
± 244 mg/day. There were highly significant improvements in overall relapse rate, manic/mixed
relapse rate, and depression relapse rate in the period during quetiapine treatment compared with
the period before quetiapine was initiated. The calculated relative risk of relapse in the absence of
quetiapine treatment was 2.9 overall (95% confidence interval, 1.5~5.6), 3.3 for manic/mixed
relapse (95% confidence interval, 1.5~7.1), and 2.4 for depressive relapse (95% confidence interval,
1.3~4.4). The mean Clinical Global Impression scores improved significantly from baseline during
26 weeks of quetiapine treatment in 21 patients (p = 0.002) and remained significantly better during
a 52-week treatment period in 13 patients (p = 0.036).
Conclusion: Long-term treatment with quetiapine combination therapy reduced the probability
of manic/mixed and depressive relapses and improved symptoms in patients with bipolar I disorder
who had inadequate responses to ongoing standard treatment.
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Introduction
Type I bipolar disorder is a severe and usually chronic
mood disorder that causes significant illness and life dis-
ruption and is characterized by recurring episodes of
mania and depression.
The goals of pharmacological treatment for bipolar disor-
der are to stabilize mood and achieve remission from
manic and depressive episodes and, after completing an
acute phase of treatment, maintain remission and prevent
the recurrence of episodes. In practice, these goals are
often achieved by treatment with traditional mood-stabi-
lizing agents, such as lithium, valproate, and/or lamotrig-
ine, with addition of an antipsychotic or other
psychotropic agents [1]. In randomized, placebo-control-
led trials, lithium has been observed to reduce the risk of
relapse by 41% and increase the time to requirement of
additional medication for a manic or depressive episode
(median survival time of 170 days versus 93 days for pla-
cebo [2-4]. When compared with placebo, lamotrigine
also increased the time to intervention for a manic or
depressive episode (median survival time of 200 days ver-
sus 93 days), but was notable for its superiority to lithium
in preventing depressive relapse (57% versus 46% of
patients were intervention-free for depression over 1 year
[4]. Ideally, the risk of drug interactions, adverse events,
and potential benefit for the individual patient must be
evaluated for each additional medication and
combination.
Although many combinations of these therapies are in
common usage, longitudinal studies of patients with
bipolar disorder in the community indicate that a large
proportion of individuals remain ill or have serious symp-
toms for significant periods of time, despite treatment
with several different medications during the course of the
studies [5-8]. These observations suggest there is a contin-
uing need for systematic investigations of therapeutic
options for patients, particularly those with refractory
disease.
Quetiapine has been shown to be effective either as com-
bination therapy or monotherapy for the treatment of
bipolar mania [9-11], and as monotherapy for the treat-
ment of bipolar depression [12]. These studies have dem-
onstrated that even in the absence of psychotic symptoms,
patients benefit from quetiapine therapy during mania
and depression. In general, atypical agents such as
quetiapine are recommended for patients with bipolar
disorder over conventional antipsychotic agents due to
the more benign side-effect profile associated with atypi-
cals [1].
In open-label trials, quetiapine has been found to reduce
symptoms, with a well-tolerated side-effect profile for
patients with poorly controlled bipolar and schizoaffec-
tive mood disorders [13], as well as rapid-cycling type I
bipolar disorder [14]. These studies were carried out for
12 to 20 weeks with patients whose previous dose of
mood-stabilizing medication was either discontinued or
maintained. Large, randomized, clinical studies demon-
strated the efficacy and tolerability of quetiapine as short-
term (3 months) monotherapy and combination therapy
during episodes of mania [11,15,16]. However, the effects
of longer-term therapy with quetiapine for patients with
refractory disease are less well understood. This study was
designed to determine the long-term clinical efficacy of
adding quetiapine to ongoing medications in patients
who were responding inadequately to these medications.
Symptomatology and relapse rates were evaluated during
combination therapy for 26 to 78 weeks.
Method
Patients
For participation in the study, patients had to be 18 years
of age or older and had to fulfill the DSM-IV diagnostic
criteria for bipolar I disorder [17]. Exclusion criteria
included pregnancy, breastfeeding in women, and a
recent history of alcohol or drug abuse in both men and
women. Consent for the study was obtained after giving
patients a complete description of the study. Inadequate
prior response to previous therapies was defined as the
patient having failed to respond to various treatment strat-
egies, such as lithium, including substitution or augmen-
tation with other mood stabilizers and antipsychotics.
Quetiapine dosing
Quetiapine was introduced at an initial dose of 25 mg
during ongoing treatment with each patient's psycho-
tropic medication (mood stabilizers, typical and atypical
antipsychotics other than quetiapine; Table 1). The dose
was increased from 25 mg per day for the first 2 days to 50
mg for 2 more days, and then adding 50 mg every 2 days
until a clinical response was achieved. This dose was
maintained for the duration of the study. Patients were
seen every 15 days (or more frequently if needed) to assess
response and side effects, to record adherence to medica-
tion, and to adjust doses as necessary. Patients were rated
Table 1: Patients' ongoing medication
Medication Number of patients
Carbamazepine 1
Chlorpromazine 2
Clozapine 2
Gabapentin 1
Haloperidol 5
Lithium 13
Olanzapine 5
Risperidone 2
Sodium valproate 2Clinical Practice and Epidemiology in Mental Health 2005, 1:7 http://www.cpementalhealth.com/content/1/1/7
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by the same clinician throughout the study period.
Patients could be withdrawn from participation in the
study at their request or on the basis of clinical judgment
or abnormal safety assessments.
Psychopathologic evaluation and severity assessments
were performed at baseline and at every visit, including an
overall opinion in several areas: seriousness of the illness,
general improvement, rate of therapeutic efficacy, and
assessment of various psychiatric symptoms.
Calculation of relative risk of relapse
The number of relapse events per patient-years of treat-
ment were calculated and compared for the total patient
population (N = 21) during the period 12 to 38 weeks
before beginning quetiapine and during the period of
quetiapine treatment. The following clinical events were
included in the calculation of relapse rates before and dur-
ing treatment with quetiapine: rehospitalization at the
discretion of the patient's attending physician, any treat-
ment in a day hospital or clinic, and an increase of 1 or
more in Clinical Global Impression (CGI) score that was
accompanied by a change in therapy.
Clinical Global Impression
Clinical response was evaluated using the CGI scale [18],
which was administered to all patients at the beginning of
the follow-up and at 12 and 26 weeks. In a subgroup of
patients who completed 52 weeks of treatment, a compar-
ison was made between the baseline and Week 52 CGI
scores.
Statistical analysis
Confidence intervals to compare the relative risk of
relapse were calculated using the simplified method of
Miettinen [19]. Mean CGI scores were compared using a
one-way analysis of variance (ANOVA) test.
Results
Patients
Twenty-one patients (14 men, 7 women; mean age 40.7 ±
12.7 years) who were receiving various medications for
type I bipolar disorder, were treated with quetiapine in
combination with their previous medication (Table 1).
The final dose of quetiapine (mean 518 mg/day ± 244
mg/day) was maintained for 26 to 78 weeks. Thirteen
patients received combination therapy for more than 52
weeks.
Efficacy
A statistically significant decrease in overall relapse rate
was observed during 26 to 78 weeks of quetiapine therapy
compared with the 12 months previous to the introduc-
tion of quetiapine, from 12 relapse events per 8.1 person-
years (1.5) to 10 relapse events per 19.5 person-years (0.5)
(Fig. 1). The relative risk of relapse in the absence of
quetiapine therapy was 2.9 (95% confidence interval,
1.5~5.6).
Similarly, the rates of manic/mixed relapse and depressive
relapse were significantly decreased during the 26- to 78-
week period of quetiapine treatment (Fig. 1). Manic or
mixed relapses occurred at a rate of 8 events per 8.1 per-
Rate of overall, manic/mixed, and depressive relapses/year before and after the addition of quetiapine to ongoing therapy Figure 1
Rate of overall, manic/mixed, and depressive relapses/year before and after the addition of quetiapine to ongoing therapy.
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son-years (0.98) in the 12 months before quetiapine ther-
apy compared with 6 events per 19.5 person-years (0.3)
during quetiapine therapy, for a relative risk of relapse of
3.3 (95% CI, 1.5~7.1). Depressive relapses occurred at a
rate of 4 events per 8.1 person-years (0.49) before initia-
tion of quetiapine therapy versus 4 events per 19.5 per-
son-years (0.2) during quetiapine therapy, for a relative
risk of relapse of 2.4 (95% CI, 1.3~4.4).
In 21 patients whose symptoms were assessed at baseline
and after 12 and 26 weeks of quetiapine therapy, signifi-
cant (p = 0.002) improvements in mean CGI score were
observed at Week 26 (Fig. 2). The improvement in mean
CGI score remained significant (p = 0.036) in 13 patients
who were evaluated after 52 weeks of treatment (Fig. 2).
Safety
The most frequent side effects reported during quetiapine
therapy were mild. These side effects were: dry mouth (4
patients; 19.0%), transient drowsiness (4 patients;
19.0%), sedation (3 patients; 14.3%), headache (2
patients; 9.5%), and constipation (2 patients; 9.5%). One
patient discontinued quetiapine therapy in the second
week of the study due to hypotension and drowsiness.
There were no incidents of tardive dyskinesia or EPS.
Discussion
Patients with bipolar I disorder who have inadequate
responses to standard pharmacological therapy remain a
common problem, despite the wide array of psychotropic
agents that may be utilized [20]. This open-label study has
demonstrated that long-term therapy with quetiapine
may benefit patients by improving global symptoms of
bipolar disorder and reducing the rate of depressive
relapses as well as manic/mixed relapses. In this study,
treatment with quetiapine for 26–78 weeks of treatment
was associated with significant improvements in relapse
rates and symptoms that were achieved with 26 weeks of
treatment in 21 patients and maintained for more than 52
weeks in a subset of 13 patients. These results, while in
agreement with a recent large, randomized, double-blind
study that established significant improvements in bipo-
lar depressive symptoms [12] as well as several clinical tri-
als showing efficacy for patients with symptoms of mania
[11,15,16], also suggest that the treatment effect observed
with quetiapine is maintained in the long-term.
For each patient, long-term quetiapine treatment was
added to ongoing medication, which included several
classes of psychotropic therapies, such as traditional
mood stabilizers and anticonvulsants, typical antipsy-
chotic agents, and atypical antipsychotic agents. While
polypharmacy with several kinds of psychotropic thera-
pies is common in adults and children with bipolar disor-
der in the community [5,21], systematic studies of long-
term antipsychotic therapy have generally used only tradi-
tional mood stabilizers as adjunctive therapy [22-25].
This study showed that adding quetiapine to a variety of
ongoing therapies was well tolerated and associated with
a low incidence of adverse events over the long term.
Although the cause is unknown, several studies have sug-
gested an increased rate of antipsychotic-induced tardive
dyskinesia and extrapyramidal symptoms (EPS) in
patients with affective disorders compared with patients
with schizophrenia [26-29]. Of particular importance for
patients with affective disorders, no increase in tardive
dyskinesia or EPS was reported during quetiapine therapy
in this study.
Similar results have been reported in a small, open-label,
88-week study of 10 adolescents with schizoaffective dis-
order or bipolar disorder [30], indicating that quetiapine
treatment is effective and well tolerated for long-term
treatment in this population as well.
This study has a number of limitations, including small
sample number and lack of a comparator. Furthermore,
the design of an open-label study does not include rand-
omization techniques and blinding of investigators to
patient status, which may introduce selection bias. How-
Mean CGI scores in patients with bipolar disorder followed  up to Week 52 Figure 2
Mean CGI scores in patients with bipolar disorder followed 
up to Week 52. F = 6.92; †p = 0.002; F = 4.91; *p = 0.036
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ever, albeit a different study population, similar observa-
tions with quetiapine were reported in a study of
comparable design [30]. Nevertheless, large, randomized,
double-blind, placebo-controlled studies are needed to
explore the benefits of adding long-term quetiapine to
standard therapies for bipolar disorder.
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